{"classes":[{"categories":[{"measurements":[{"comment":"Could not be determined due to early study closure (due to clinically significant toxicity, slow accrual and significant adverse events also reported with the combination of AZD1775 and chemoradiation in other studies)","groupId":"OG000","value":"NA"},{"comment":"Could not be determined due to early study closure (due to clinically significant toxicity, slow accrual and significant adverse events also reported with the combination of AZD1775 and chemoradiation in other studies)","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"To determine the recommended phase II dose (RP2D) and safety profile of AZD1775 in combination with radiotherapy and concurrent cisplatin in patients with gynecological cancers.","groups":[{"description":"Patients undergo external beam radiation therapy on days 1-5, receive AZD1775 PO on days 1, 3, and 5, and receive cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.","id":"OG000","title":"Treatment (Radiation Therapy, AZD1775 3 Days/Week, Cisplatin) Dose Level 1"},{"description":"Patients undergo external beam radiation therapy on days 1-5, receive AZD1775 PO on days 3 and 5, and receive cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.","id":"OG001","title":"Treatment (Radiation Therapy, AZD1775 2 Days/Week, Cisplatin) Dose Level -1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants that were evaluable for response.","reportingStatus":"POSTED","timeFrame":"Up to week 5","title":"Recommended Phase 2 Dose Defined as the Dose Level With < 1/6 Patients With Dose Limiting Toxicities","type":"PRIMARY","unitOfMeasure":"Participants"}